Skip to main content

Lexicon to Test Compounds with Nuevolution's Chematics

NEW YORK (GenomeWeb News) – Lexicon Pharmaceuticals said today it will use Nuevolution’s technology to identify small molecule lead compounds against a range of highly validated drug targets.
 
Under the agreement, Lexicon will pay Nuevolution an upfront payment and would also pay milestone payments and royalties on compounds that are identified using the Nuevolution Chemetics technology if candidate molecules advance through preclinical and clinical development and onto the market.
 
Copenhagen, Denmark-based Nuevolution also will have a future option to expand its involvement through a cost and profit sharing arrangement.
 
Lexicon specifically will use Nuevolution’s Chemetics platform to screen multiple fragment-based small molecule libraries. The validated targets were identified using Lexicon’s Genome5000 program, which the company used to explore physiological and behavioral function for nearly 5,000 genes by studying corresponding genes in knockout mice.
 
Nuevolution uses DNA labeling as part of its Chematics fragment-based drug screening platform, which helps identifty potent drug leads of higher quality and more quickly than other high-throughout screening approaches, according to the company.
 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.